WHEN THE RISK DATA from several studies of HLA association with malignancy are combined, there is an indication of an association of HLA-A1 with Hodgkin's disease, HLA-A2 with acute lymphocytic leukaemia, and Sin 2 (an HLA-B antigen) and Sin 2a (an HLA-D antigen) with nasopharyngeal carcinoma in Singapore Chinese (reviewed by Rogentine, 1979) . In most of the studies in lung cancer, however, no significant differences in HLA antigen frequency have been found at diagnosis, though there have been several reports of HLA association with prognosis.
In a retrospective study of 14 surgically cured patients it was reported that HLA-AW19 and HLA-B5 were associated with a better prognosis (Dellon et al., 1975) . In patients who were prospectively typed they also found a clear association of these two antigens with prognosis in patients with squamous or adenocarcinomas. This was confirmed in a 2-year follow-up study, when patients with either antigen had a 57% (12/21) chance of being alive and disease free 2 years after diagnosis, compared to only a 13% chance (6/48) if they lacked these antigens (Rogentine et al., 1977) . This observation has been complemented by a report of a retrospective study of 20 patients with non-oat-cell bronchogenic carcinoma of the lung, alive at least 1 year after diagnosis, in which 50% of the survivors were found to have one or other of these antigens (Weiss et al., 1980) . However, in another report 20 retrospectively typed patients who had survived more than a year after surgery were found to have an increased frequency of HLA-B8 (Sengar et al., 1977 authors also reported a decreased frequency of HLA-A2 in the 37 patients they studied. More recently a prospective and retrospective study was reported in which the frequency of HLA-B 12 was found to be raised in all patients, and HLA-A29 was found to be raised in patients who had died, whereas the frequency was normal in 5-year survivors (Tongio et al., 1980) . The aim of this study was to investigate the frequency of HLA antigens in people with bronchogenic carcinoma and to determine whether the reported associations with prognosis applied to the lungcancer patients in this region.
MATERIALS AND METHODS
Patients and controls. Eighty-six patients with lung cancer of various histological types, who were eligible for entry into a controlled trial of passive immunochemotherapy after resection of their cancer (Newman et al., 1977) , and 14 patients with small-cell anaplastic carcinoma of the lung who entered a pilot study of chemotherapy and radiotherapy, w%ere investigated. Peripheral-blood lymphocytes were obtained before surgery or other therapeutic procedures and used for typing immediately, or frozen down in liquid N2 and stored for typing at a later date. Details of the freezing, storage and thawing procedures have been published elsewhere (Ford et al., 1979) . In cases where pre-treatment blood samples were not available, lymphocytes were obtained from blood samples taken during outpatient follow-up. For Analyses.-HLA antigen frequencies were compared between groups by means of x2 analysis using Yate's correction. Relative liability (Edwards, 1974) was also plotted.
RESULTS
The percentage frequencies of HLA antigens in the 100 lung-cancer patients and 151 controls are shown in Table I Comparison of the overall lung-cancer group with the control group shows no significant difference in the frequency of the antigens studied, though the percentages differ. There were significant differences between the lung-cancer group and controls for: an increased frequency of HLA-B15 in anaplastic tumours (P < 0.05); a decreased frequency of HLA-B12 in adenocarcinomas (P < 0.05); an increased frequency of HLA-B5 in small-(oat-) cell anaplastic carcinomas (P < 0.05) and an increased frequency of HLA-B40 in Stage III patients (P = 0 05).
Although none of the antigens was associated with lung cancer, from Fig. 1 it can be seen that there is a higher relative risk of being HLA-BW22 positive and having lung cancer (plotting 3-fold above the median line). The low frequency of this antigen in the normal population (3/151) and the small number of cancer patients positive for HLA-BW22 (6/100) makes this observation non-significant. However, when the frequency of HLA-BW22 in the 47 patients alive at least 22 years after surgery is compared with the normal population, there is a significant increase in the frequency of the antigen in the survivors (plotting more than 4-fold above the median line (P < 0.05) (Fig. 2) .
In Table II HLA frequency and survival 37-5% (6)* 50% (4) 45% (10) 58% (37) 62-5% (10) 50% (4) 55% (12) 42% (27 There is an indication of an increase of HLA-B15 in anaplastic tumours; a decrease of HLA-B12 in adenocarcinomas;
an increase of HLA-B5 in small-cell anaplastic carcinomas and an increase of HLA-B40 in Stage III patients. However, if each P value for these significant differences is multiplied by the number of antigens looked at, they all become nonsignificant. This, together with the relatively small numbers in the subgroups, makes us very cautious in putting too much emphasis on the apparent associations.
An interesting observation was the increased frequency (non-significant) of HLA-BW22 in the lung cancer group and in particular the significant association of this antigen with patients alive at least 6;13 21 years after surgery. Again, if the P value is multiplied by the number of antigens looked for, it becomes non-significant. Also, because the frequency of HLA-BW22 is low in the normal population (3/151) and the number of cancer patients positive for this antigen is also small (6/ 100; or 5/47 in survivors) conclusions regarding the significance of the association with a better prognosis must be tentative.
A second finding was that in patients with a minimum follow-up of 21 years and a maximum of 5-years from surgery we have been unable to confirm the significant association of HLA-AW19 and/or HLA-B5 with a good prognosis, as reported by the NIH group for squamous and adenocarcinomas of the lung (Dellon et al., 1975; Rogentine et al., 1977) and supported by Weiss et al. (1980) . Similarly, we found no association of HLA-B8 with better prognosis in this group of patients, although Sengar et al. (1977) have reported such an association. The best association was seen for HLA-BW22, when 83% of antigenpositive individuals were alive at least 22 years after surgery compared with 52.5% of patients positive for antigens other than HLA-BW22, though this was not significant.
Whether this lack of correlation with other studies is due to differences in the population studied, the size of the groups, or the length of follow-up is unclear. Probably all three factors influence the results. The patient population studied for prognosis was heterogeneous with respect to tumour histology. As might be expected, there were more SCA patients in the dead group than in those alive, but overall the number of anaplastic, squamous and adeno-carcinomas were similar in those alive and dead. Four of the alive BW22-positive patients were Stage I. However, 46% of dead patients were Stage I and none of these were BW22-positive, so association with a particular stage appears unlikely.
Although the study was not performed retrospectively it is not entirely prospective, in that not all the lymphocyte samples were obtained before treatment. We feel these data indicate the need for larger, prospective studies to resolve some of these questions, especially with regard to HLA-BW22. Any association of an antigen with prognosis may aid considerably in our ability to tailor the treatment to individual patients, as well as giving a clue to genetic factors which may be involved in susceptibility or resistance to lung cancer. The apparent associations for other antigens with histology and stage would also be clarified by such studies.
